hi,
I got more clarity today. this Arbutus trial comprises biweekly doses of 3 month instead of monthly ( as they seen higher hbsag log reduction-1 with higher level of dose). I heard Ar-1467 flair the inflammation ( and thats why they give steroid before drug) and can make hep much worse then previous state. but due to biweekly drug it may also prove to reduce hbsag quickly.
kindly can someone provide their opinion.
I personally was accepted for the latest ARC-520 trial but decided not to start with it when I saw 1-2 cases of heart-block side effects out of 48 or 78 cases (forgot the numbers)
ARC-520 trial was even running with NUCs and Peg-interferon in a combo, so there was a small chance of a cure...but in your case (as far as I can see) there won't be any interferon included...there your chance of the cure would be close to 0%...and your hbsag would rebound once the trial would end....in other words not worth risking the possible side-effects.
Assuming this Rnai works similarly to failed ARC from arrowhead the medicine would only temporarily reduce your hbsag but not permanently. It seems to me there is virtually no chance of cure, thus it wouldn't be worth enrolling into this.
It is arbutus1467. Previously it was monthly once inteavenous administartive( hbsabs reduction 1log- i am not sure how much it is as mine current is 9k hbsag - down from baseline 12k.) ,now they want cohort on bi-weekly basis for 3 month. They will do blood intravenous drug administration.
Can anyone let me know pros and cons on clinical trial on this and what you think on arbutus worth taking risk?
Get more details and post them here...however it doesn't look as an attractive option to me...